Ara-290 10mg

ARA-290 is a peptide of pronounced interest in scientific circles due to its potential to support nerve regeneration, to modulate inflammatory processes and to participate in mechanisms related to cellular protection, neuropathy and tissue repair.

What is ARA-290?

ARA-290 is a synthetic peptide developed as a derivative of erythropoietin (EPO) – a hormone that is naturally produced in the body and is responsible for stimulating the production of red blood cells.

Unlike erythropoietin itself, which directly affects hematopoiesis, ARA-290 was designed to preserve its protective and anti-inflammatory properties without stimulating the formation of red blood cells. This is the key difference that makes it significantly more targeted and safer for research purposes.

The peptide acts by activating tissue-protective receptors that participate in the regulation of inflammation, cellular protection and tissue repair. It is this mechanism that positions it as a strong candidate in research on neuropathies, chronic pain and inflammatory conditions.

ARA-290 is being actively studied in conditions such as diabetic neuropathy, fibromyalgia and other conditions related to nervous system damage. Data from clinical observations indicate that it may help reduce pain, improve nerve function and overall quality of life.

In addition, the peptide is being considered in the context of metabolic and inflammatory processes, with research into its potential to support tissue repair, improve organ function and reduce inflammatory markers in the body.

Because of these properties, ARA-290 is used in studies related to nerve regeneration, inflammation control and recovery of the body after injury.

The peptide is not approved as a medicinal product by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) and is used mainly in scientific and research settings.

What are the benefits of ARA-290?

• Reduction of inflammation

ARA-290 helps regulate inflammatory processes in the body.

• Alleviation of chronic pain

It is associated with a reduction of neuropathic pain and discomfort.

• Support for the nervous system

Supports repair and protection of nervous tissue.

• Improvement of nerve function

It is associated with improved sensitivity and nerve conduction.

• Improvement of quality of life

Positive effects have been observed in conditions such as fibromyalgia.

• Support in metabolic conditions

It is being studied in conditions such as diabetic neuropathy.

• Cellular protection

Helps protect cells during stress and injury.

• Improvement of organ function

It is associated with positive effects on the kidneys and other organs.

Clinical trials on ARA-290

ARA-290 is the subject of a number of clinical studies that show promising results in neuropathic conditions and chronic pain.

In one of the large clinical trials in patients with diabetic neuropathy, a significant reduction in pain and improvement in symptoms was observed. Other studies in people with fibromyalgia show reduced pain and improved quality of life.

Additional data indicate that the peptide may help protect the nervous system, improve metabolic processes and accelerate tissue repair.

Overall, study results show a solid potential for application in the context of inflammatory and neurological conditions.

Proper administration and dosage of ARA-290 within a research protocol

ARA-290 is usually administered by subcutaneous injection, with research protocols most commonly using doses in the range of 3 mg to 4 mg daily.

Administration is usually once daily, and the course duration may vary up to about 1–2 months depending on the objectives.

Possible side effects of ARA-290

ARA-290 is considered a well-tolerated peptide with a low risk of side effects.

Most commonly mild discomfort or redness at the injection site is observed. In rare cases a temporary increase in blood pressure or blood glucose may be reported, which usually resolves quickly.

Overall, the peptide is characterized by good tolerability and minimal adverse reactions when used correctly.

Comparison of ARA-290 with other peptides

ARA-290 belongs to the group of tissue-protective and neuroregenerative peptides. Unlike peptides that stimulate growth hormone release and aid in building muscle mass and burning fat, it is primarily targeted at the nervous system, inflammatory control and repair of damaged tissues.

ARA-290 vs BPC-157

BPC-157 is better known for its effect on tendons, muscles, joints and general tissue regeneration. ARA-290 is more specifically targeted at nervous tissue, neuropathic discomfort and cellular protection. In short, BPC-157 is a broader regenerative peptide, while ARA-290 is more neurologically oriented.

ARA-290 vs TB-500

TB-500 is mainly associated with cell migration, repair and tissue mobility after injuries. ARA-290 works by a different mechanism and is more strongly linked to anti-inflammatory signaling and nerve regeneration. TB-500 is more popular for sports injuries, while ARA-290 is for nerve stress and sensitivity.

ARA-290 vs KPV

KPV is a short-chain peptide with a primarily anti-inflammatory profile, especially for skin, intestines and mucous membranes. ARA-290 also has anti-inflammatory potential but is more strongly targeted at the nervous system and protection of neuronal tissue.

ARA-290 vs GHK-Cu

GHK-Cu is better known for effects on skin, collagen, hair and general anti-aging recovery. ARA-290 is significantly more focused on neural structures, neuropathic conditions and functional recovery.

The information on this website has been gathered and summarized from multiple scientific studies and analyses.

It is purely informational in nature and is not intended for the diagnosis, treatment or prevention of diseases.

The products offered on the site are not classified as drugs or medical devices and are intended only for laboratory and scientific research purposes.